BTG plc (LSE: BTG), the global healthcare company, announced today that the first EKOS„¢ CU 4.0 units have been shipped from BTGs facility in Bothell (Washington, US) to Europe, where full commercial launch will begin. New features of the EKOS„¢ CU 4.0 include an interactive colour touchscreen, a built-in battery and separate ports for managing two EKOS„¢ devices simultaneously.
These improvements simplify bilateral treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT). Using CU 4.0, physicians can treat both pulmonary arteries and can easily monitor and manage two EKOS„¢ devices at the same time.
European patients with PEs and DVTs have already successfully been treated with EKOS„¢ CU 4.0 during a limited release of the product.
Professor Nils Kucher, Director of Clinic of Angiology at University Hospital in Zurich, Switzerland said: Ive used EKOS„¢ therapy for over 10 years. This latest innovation of the technology is a big step for simplifying thrombosis treatment.
EKOS„¢ is the only device to have both FDA Clearance and a CE Mark  for the treatment of PE. The system includes an ultrasonic device that uses acoustic pulses, which enable quick and safe dissolution of blood clots and restore blood flow in patients with PE, DVT and peripheral arterial occlusions.
BTG is a global healthcare company focused on Interventional Medicine. Our innovative medical technology helps physicians treat their patients through minimally invasive procedures. We have a growing portfolio of products that advance the treatment of cancer and vascular conditions. BTGs Pharmaceuticals business provides products that help patients overexposed to certain medications or toxins. To learn more about BTG, please visit: btgplc.com.
EKOS is a registered trademark of EKOS Corporation, a BTG International group company. BTG and the BTG roundel logo are registered trademarks of BTG International LTD.
Product availability varies by country. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. Prior to use, please refer to the applicable Instructions for Use (IFU) for complete product indications, contraindications, warnings, and precautions.
Andy Burrows, VP Corporate & Investor Relations
(0)20 7575 1741; Mobile: +44 (0)7990 530 605
Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7815
Chris Sampson, Corporate Communications Director
(0)20 7575 1595; Mobile: +44 (0)7773 251 178
Ben Atwell/Simon Conway +44 (0)20 3727 1000